ES2159678T3 - Formulaciones de aerosol en suspension. - Google Patents

Formulaciones de aerosol en suspension.

Info

Publication number
ES2159678T3
ES2159678T3 ES96200109T ES96200109T ES2159678T3 ES 2159678 T3 ES2159678 T3 ES 2159678T3 ES 96200109 T ES96200109 T ES 96200109T ES 96200109 T ES96200109 T ES 96200109T ES 2159678 T3 ES2159678 T3 ES 2159678T3
Authority
ES
Spain
Prior art keywords
suspension
aerosol formulations
aerosol formulation
amount
hfc134a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96200109T
Other languages
English (en)
Inventor
Robert K Schultz
David W Schultz
Martin J Oliver
Robert A Moris
Philip A Jinks
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
3M Co
Original Assignee
Minnesota Mining and Manufacturing Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2159678(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Minnesota Mining and Manufacturing Co filed Critical Minnesota Mining and Manufacturing Co
Application granted granted Critical
Publication of ES2159678T3 publication Critical patent/ES2159678T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Abstract

UNA FORMULACION DE AEROSOL DE SUSPENSION QUE COMPRENDE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE FARMACO MICRONIZADO SELECCIONADO DE ACETATO DE PIRBUTEROL E HIDROCLORURO DE PIRBUTEROL, Y UN PROPELENTE QUE COMPRENDE HFC 227 LA FORMULACION ESTANDO SUSTANCIALMENTE LIBRE DE SURFACTANTE PERFLUORADO. UNA FORMULACION DE AEROSOL DE SUSPENSION QUE COMPRENDE UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE SULFATO DE ALBUTEROL MICRONIZADO Y HFC 227 COMO SUSTANCIALMENTE EL UNICO PROPELENTE.
ES96200109T 1991-12-18 1992-12-11 Formulaciones de aerosol en suspension. Expired - Lifetime ES2159678T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80979191A 1991-12-18 1991-12-18
US81040191A 1991-12-18 1991-12-18
US87803992A 1992-05-04 1992-05-04

Publications (1)

Publication Number Publication Date
ES2159678T3 true ES2159678T3 (es) 2001-10-16

Family

ID=27420051

Family Applications (3)

Application Number Title Priority Date Filing Date
ES96200109T Expired - Lifetime ES2159678T3 (es) 1991-12-18 1992-12-11 Formulaciones de aerosol en suspension.
ES00123885T Expired - Lifetime ES2216800T3 (es) 1991-12-18 1992-12-11 Formulaciones de aerosol en suspension.
ES93901414T Expired - Lifetime ES2099415T3 (es) 1991-12-18 1992-12-11 Formulaciones de aerosol en suspension.

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES00123885T Expired - Lifetime ES2216800T3 (es) 1991-12-18 1992-12-11 Formulaciones de aerosol en suspension.
ES93901414T Expired - Lifetime ES2099415T3 (es) 1991-12-18 1992-12-11 Formulaciones de aerosol en suspension.

Country Status (13)

Country Link
US (2) US6743413B1 (es)
EP (3) EP1086688B1 (es)
JP (2) JP3908269B2 (es)
AT (3) ATE150296T1 (es)
AU (2) AU675633B2 (es)
CA (2) CA2320129C (es)
DE (3) DE69232034T2 (es)
DK (3) DK0617610T3 (es)
ES (3) ES2159678T3 (es)
GR (2) GR3022874T3 (es)
NZ (1) NZ246421A (es)
PT (2) PT1086688E (es)
WO (1) WO1993011747A1 (es)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243062A (en) 1991-06-10 1993-09-27 Schering Corp Aerosol containing medicament and 1,1,1,2-tetrafluoroethane
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
CA2125666C (en) * 1991-12-12 2002-07-16 Rachel Ann Akehurst Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
ES2079210T3 (es) * 1991-12-12 1996-01-01 Glaxo Group Ltd Formulacion farmaceutica de aerosol.
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
PT1086688E (pt) * 1991-12-18 2004-06-30 Minnesota Mining & Mfg Formulacoes de aerossol em suspensao
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
WO1995017195A1 (en) * 1993-12-20 1995-06-29 Minnesota Mining And Manufacturing Company Flunisolide aerosol formulations
AU709783B2 (en) * 1994-03-14 1999-09-09 Abbott Laboratories Aerosol drug formulations containing vitamin E
US5508023A (en) * 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
DE69633222T2 (de) * 1995-02-24 2005-09-08 Elan Pharma International Ltd. Nanopartikel-dispersionen enthaltende aerosole
GB9526392D0 (en) 1995-12-22 1996-02-21 Glaxo Group Ltd Medicaments
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
GB9620187D0 (en) † 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
US6413496B1 (en) 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
EA003665B1 (ru) * 1997-09-29 2003-08-28 Нектар Терапьютикс Перфорированные микрочастицы и способ их использования
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
PT1102579E (pt) * 1998-08-04 2003-07-31 Jago Res Ag Formulacoes de aerossol medicinais
DE19847969A1 (de) * 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
EA003960B1 (ru) * 1998-10-17 2003-10-30 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Устойчивый при хранении концентрат биологически активного вещества формотерола
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
US6739333B1 (en) 1999-05-26 2004-05-25 Boehringer Ingelheim Pharma Kg Stainless steel canister for propellant-driven metering aerosols
DE19924098A1 (de) * 1999-05-26 2000-12-07 Boehringer Ingelheim Pharma Edelstahlkanister für treibgasbetriebene Dosieraerosole
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
GB9924808D0 (en) * 1999-10-21 1999-12-22 Glaxo Group Ltd Medicament dispenser
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
AU5070100A (en) * 2000-05-22 2001-12-03 Chiesi Farma Spa Stable pharmaceutical solution formulations for pressurised metered dose inhalers
GB0014869D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
JP2005504715A (ja) 2000-12-29 2005-02-17 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続放出特性を有する吸入用粒子
PT1273292E (pt) 2001-07-02 2004-10-29 Chiesi Farma Spa Formulacao optimizada de tobramicina para aerossolizacao
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
DE10234165B4 (de) * 2002-07-26 2008-01-03 Advanced Micro Devices, Inc., Sunnyvale Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
EP1671942B2 (en) 2002-12-10 2014-07-23 Sunovion Pharmaceuticals Inc. Aerosol formulation comprising levalbuterol L-tartrate salt
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US20040226556A1 (en) 2003-05-13 2004-11-18 Deem Mark E. Apparatus for treating asthma using neurotoxin
TW200510298A (en) 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
AU2004246819A1 (en) 2003-06-13 2004-12-23 Nycomed Gmbh Formoterol and ciclesonide combination
WO2005032521A2 (en) * 2003-10-02 2005-04-14 Collegium Pharmaceutical, Inc. Non-flammable topical anesthetic liquid aerosols
US20060188449A1 (en) * 2003-10-03 2006-08-24 Jane Hirsh Topical aerosol foams
SG147453A1 (en) * 2003-10-20 2008-11-28 Schering Corp Pharmaceutical aerosol compositions
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US20050255048A1 (en) * 2004-05-15 2005-11-17 Collegium Pharmaceutical, Inc. Sprayable formulations for the treatment of acute inflammatory skin conditions
DE602005009012D1 (de) * 2004-10-12 2008-09-25 Generics Uk Ltd Rmulierungen, worin die partikel durch präzipition in einem aerosolbehälter gebildet werden
EP1949891A1 (en) 2004-10-12 2008-07-30 Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
WO2007008427A2 (en) * 2005-07-08 2007-01-18 Xemplar Pharmaceuticals, Llc Aerosol compositions and methods
PL1921919T3 (pl) 2005-07-14 2012-09-28 Lithera Inc Ulepszona lipolityczna formulacja o podtrzymywanym uwalnianiu do traktowania lokalnej tkanki tłuszczowej
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
EP2061434A2 (en) * 2006-09-08 2009-05-27 The Regent of the University of California Engineering shape of polymeric micro-and nanoparticles
US7754096B2 (en) * 2007-02-01 2010-07-13 E.I. Du Pont De Nemours And Company Liquefied-gas aerosol dusting composition containing denatonium benzoate
DK2120875T3 (en) 2007-02-11 2018-10-22 Map Pharmaceuticals Inc METHOD OF THERAPEUTIC ADMINISTRATION OF DHE TO POSSIBLE QUICK PREVENTION OF MIGRANE AT THE MINIMUM OF THE SIDE EFFECT PROFILE
US8652443B2 (en) * 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
US8483831B1 (en) 2008-02-15 2013-07-09 Holaira, Inc. System and method for bronchial dilation
AU2009244058B2 (en) 2008-05-09 2015-07-02 Nuvaira, Inc Systems, assemblies, and methods for treating a bronchial tree
US8236862B2 (en) 2009-02-06 2012-08-07 University Of Southern California Therapeutic compositions comprising monoterpenes
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
SG178036A1 (en) 2009-07-15 2012-03-29 Theravance Inc Crystalline freebase forms of a biphenyl compound
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
CA2779135C (en) 2009-10-27 2018-09-04 Innovative Pulmonary Solutions, Inc. Delivery devices with coolable energy emitting assemblies
US8911439B2 (en) 2009-11-11 2014-12-16 Holaira, Inc. Non-invasive and minimally invasive denervation methods and systems for performing the same
CN106618731B (zh) 2009-11-11 2020-08-07 努瓦拉公司 用于处理组织和控制狭窄的系统、装置和方法
JP2013512193A (ja) 2009-11-24 2013-04-11 ギリアード サイエンシーズ， インコーポレイテッド 慢性閉塞性肺疾患の処置のための吸入型ホスホマイシン／トブラマイシン
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
CA2828833C (en) 2010-03-03 2020-11-03 Neonc Technologies Inc. Pharmaceutical compositions comprising monoterpenes
JP5908884B2 (ja) 2010-03-15 2016-04-26 ヴァージニア コモンウェルス ユニヴァーシティＶｉｒｇｉｎｉａ Ｃｏｍｍｏｎｗｅａｌｔｈ Ｕｎｉｖｅｒｓｉｔｙ 気道炎症及び粘液線毛輸送機能異常治療用のエアロゾル化したダプソン
JP5807058B2 (ja) 2010-05-10 2015-11-10 ギリアード サイエンシーズ， インコーポレイテッド 二機能キノリン誘導体
US8367829B2 (en) 2010-05-10 2013-02-05 Gilead Sciences, Inc. Bi-functional pyrazolopyridine compounds
WO2012083178A1 (en) 2010-12-17 2012-06-21 Neo Oncology Inc. Methods and devices for using isoperillyl alcohol
EP2898883B1 (en) 2010-08-27 2016-11-23 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol carbamates
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
TWI399202B (zh) 2011-03-17 2013-06-21 Intech Biopharm Ltd 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
GB201117621D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
GB201117619D0 (en) * 2011-10-12 2011-11-23 Mexichem Amanco Holding Sa Compositions
EA032734B1 (ru) 2012-05-29 2019-07-31 Парион Сайэнс, Инк. Дендримероподобные аминоамиды, обладающие активностью блокаторов натриевых каналов, для лечения сухости глаз и других заболеваний слизистых оболочек
US9012490B2 (en) * 2012-08-17 2015-04-21 Howard University Lipophilic curcumin analogs and methods of inhibiting HIV-1, treating latent HIV in the brain, and preventing HIV-mediated cognitive decline and HIV dementia
RU2671976C2 (ru) 2012-12-17 2018-11-08 Пэрион Сайенсиз, Инк. Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида
CA2896686A1 (en) 2012-12-17 2014-06-26 Parion Sciences, Inc. 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
PL2931713T3 (pl) 2012-12-17 2017-06-30 Parion Sciences, Inc. Chloro-pirazynowe pochodne karboksyamidowe do leczenia chorób, którym sprzyja niedostateczne nawilżenie błon śluzowych
CA2895816C (en) 2012-12-21 2021-02-23 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
US9398933B2 (en) 2012-12-27 2016-07-26 Holaira, Inc. Methods for improving drug efficacy including a combination of drug administration and nerve modulation
HUE038899T2 (hu) 2013-03-15 2018-12-28 Verona Pharma Plc Gyógyszer kombináció
GB201306984D0 (en) 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
ES2682105T3 (es) 2014-05-12 2018-09-18 Verona Pharma Plc Nuevo tratamiento
US9522918B2 (en) 2015-02-12 2016-12-20 Neonc Technologies, Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
WO2018102412A1 (en) 2016-11-30 2018-06-07 Neonc Technologies, Inc. A perillyl alcohol-3 bromopyruvate conjugate and methods of treating cancer
CA3101475C (en) 2018-02-08 2024-02-20 Neonc Technologies, Inc. The use of monoterpene, sesquiterpene, or their derivatives to permearbilize the blood brain barrier
US11964121B2 (en) 2021-10-13 2024-04-23 Satio, Inc. Mono dose dermal patch for pharmaceutical delivery
US11877848B2 (en) 2021-11-08 2024-01-23 Satio, Inc. Dermal patch for collecting a physiological sample

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (es) 1956-03-21 1900-01-01
US2885427A (en) 1956-11-15 1959-05-05 Dow Chemical Co Fluorination of trichloroethylene
BE556587A (es) 1957-01-31 1957-04-11
NL289785A (es) 1962-11-29
US3320125A (en) 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
US3261748A (en) 1964-07-17 1966-07-19 Dow Chemical Co 1,1,1,2-tetrafluoroethane anesthetic
GB1200886A (en) 1966-09-23 1970-08-05 Allen & Hanburys Ltd Phenylaminoethanol derivatives
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
US3897779A (en) 1973-06-27 1975-08-05 American Cyanamid Co Triamcinolone acetonide inhalation therapy
US3809294A (en) 1973-06-27 1974-05-07 American Cyanamid Co Dispensing lung contacting powdered medicaments
US3994421A (en) * 1975-09-29 1976-11-30 American Cyanamid Company Unitary therapeutic aerosol dispenser
US4405598A (en) 1976-01-30 1983-09-20 Fisons, Limited Composition for treating asthma
FI770215A (es) 1976-01-30 1977-07-31 Fisons Ltd
NL7708731A (nl) 1976-08-13 1978-02-15 Montedison Spa Werkwijze voor de bereiding van nieuwe drijf- middelsamenstellingen voor aerosolen.
JPS5325284A (en) 1976-08-19 1978-03-08 Daikin Ind Ltd Aerosol composition
US4129603A (en) 1978-02-07 1978-12-12 Imperial Chemical Industries Limited Manufacture of halogenated compounds
US4241048A (en) 1979-05-01 1980-12-23 Bristol-Myers Company Suspension composition of benzocaine
ZA81976B (en) 1980-02-15 1982-07-28 Glaxo Group Ltd Androstane carbothioates
US4352789A (en) 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
ATE3774T1 (de) 1980-05-02 1983-06-15 Schering Corporation Beclomethason-ester-solvate, verfahren zu ihrer herstellung und herstellung einer formulierung.
FI63672C (fi) 1980-05-19 1983-08-10 Orion Yhtymae Oy Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
US4311863A (en) 1980-06-11 1982-01-19 E. I. Du Pont De Nemours & Company Process for the manufacture of 1,1,1,2-tetrafluoroethane
US4710495A (en) * 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
JPS60224638A (ja) 1984-04-23 1985-11-09 Kao Corp 経皮吸収促進剤およびこれを含有する外用剤
GB8432063D0 (en) 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
GB8501015D0 (en) 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
US4767612A (en) * 1987-01-23 1988-08-30 Rorer Pharmaceutical Corporation Triamcinolone acetonide for the treatment of allergic rhinitis
US4851595A (en) 1987-07-07 1989-07-25 E. I. Du Pont De Nemours And Company Liquid phase halogen exchange process for the manufacture of 1,1,1,2-tetrafluoroethane
US4963557A (en) * 1987-09-28 1990-10-16 Smithkline Beecham Corporation Immunomodulatory azaspiranes
US5206268A (en) 1988-08-16 1993-04-27 Burroughs Wellcome Co. Medicaments
GB8820398D0 (en) 1988-08-27 1988-09-28 Fisons Plc Pharmaceutical formulation
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5776434A (en) * 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828544D0 (en) 1988-12-07 1989-01-11 Ici Plc Chemical process
DE3905726A1 (de) 1989-02-24 1990-08-30 Hoechst Ag Druckgaspackung und treibmittel fuer aerosole
US4945119A (en) 1989-05-10 1990-07-31 The Dow Chemical Company Foaming system for rigid urethane and isocyanurate foams
US4940171A (en) 1989-05-18 1990-07-10 Gilroy Gordon C Aerosol package having compressed gas propellant and vapor tap of minute size
AU633584B2 (en) 1989-06-15 1993-02-04 Tokyo Tanabe Company Limited Aerosols of pyrido(1,2-a)pyrimidine compounds
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
GB8921222D0 (en) * 1989-09-20 1989-11-08 Riker Laboratories Inc Medicinal aerosol formulations
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
DE4003270A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
US5118494A (en) 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5126123A (en) 1990-06-28 1992-06-30 Glaxo, Inc. Aerosol drug formulations
US5230884A (en) 1990-09-11 1993-07-27 University Of Wales College Of Cardiff Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations
US5292499A (en) 1990-09-11 1994-03-08 University Of Wales College Of Cardiff Method of preparing medical aerosol formulations including drug dissolved in reverse micelles
MX9203481A (es) 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5919435A (en) 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
GB9024365D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US5254755A (en) 1990-12-04 1993-10-19 Allied-Signal Inc. Partially fluorinated alkanols having a tertiary structure
US5290539A (en) 1990-12-21 1994-03-01 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US6006745A (en) * 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5190029A (en) 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5182097A (en) 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
US5182040A (en) 1991-03-28 1993-01-26 E. I. Du Pont De Nemours And Company Azeotropic and azeotrope-like compositions of 1,1,2,2-tetrafluoroethane
EP0656206B1 (en) 1991-06-10 2001-08-08 Schering Corporation Non-chlorofluorocarbon aerosol formulations
NZ243062A (en) 1991-06-10 1993-09-27 Schering Corp Aerosol containing medicament and 1,1,1,2-tetrafluoroethane
AU2178392A (en) * 1991-06-12 1993-01-12 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
US5683676A (en) 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US5736124A (en) 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5658549A (en) 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
CA2125666C (en) 1991-12-12 2002-07-16 Rachel Ann Akehurst Medicaments
US5674471A (en) 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5744123A (en) 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
ES2079210T3 (es) * 1991-12-12 1996-01-01 Glaxo Group Ltd Formulacion farmaceutica de aerosol.
PT1086688E (pt) * 1991-12-18 2004-06-30 Minnesota Mining & Mfg Formulacoes de aerossol em suspensao
GB9200148D0 (en) * 1992-01-06 1992-02-26 Minnesota Mining & Mfg Aerosol valves
US5202110A (en) 1992-01-22 1993-04-13 Virginia Commonwealth University Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants
GB9202519D0 (en) 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
US5833950A (en) 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
US5314682A (en) 1992-09-21 1994-05-24 Great Lakes Chemical Corp. Ozone friendly sterilant mixture
US5492688A (en) 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
WO1995017195A1 (en) * 1993-12-20 1995-06-29 Minnesota Mining And Manufacturing Company Flunisolide aerosol formulations
US5508023A (en) 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
GB9425160D0 (en) * 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
US6013245A (en) 1995-01-26 2000-01-11 Glaxo Group Limited Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations

Also Published As

Publication number Publication date
NZ246421A (en) 1996-05-28
DE69218455D1 (de) 1997-04-24
DK1086688T3 (da) 2004-08-16
EP0617610B1 (en) 1997-03-19
DK0617610T3 (da) 1997-10-06
CA2126244A1 (en) 1993-06-24
US6743413B1 (en) 2004-06-01
WO1993011747A1 (en) 1993-06-24
AU709052B2 (en) 1999-08-19
ATE260641T1 (de) 2004-03-15
ES2099415T3 (es) 1997-05-16
JPH07502275A (ja) 1995-03-09
DE69233319D1 (de) 2004-04-08
GR3036467T3 (en) 2001-11-30
EP0717987A3 (es) 1996-07-03
JP2004143183A (ja) 2004-05-20
DE69232034T2 (de) 2002-06-06
EP1086688B1 (en) 2004-03-03
DE69232034D1 (de) 2001-10-04
EP0717987B1 (en) 2001-08-29
EP0717987A2 (en) 1996-06-26
CA2320129C (en) 2003-02-11
CA2320129A1 (en) 1993-06-24
DE69233319T2 (de) 2005-02-17
AU1234297A (en) 1997-03-20
JP3908269B2 (ja) 2007-04-25
PT717987E (pt) 2001-12-28
US20040197273A1 (en) 2004-10-07
ES2216800T3 (es) 2004-11-01
EP0617610A1 (en) 1994-10-05
AU709052C (en) 2002-04-11
PT1086688E (pt) 2004-06-30
AU675633B2 (en) 1997-02-13
EP1086688A1 (en) 2001-03-28
ATE204743T1 (de) 2001-09-15
AU3272893A (en) 1993-07-19
DE69218455T2 (de) 1997-10-23
GR3022874T3 (en) 1997-06-30
DK0717987T3 (da) 2001-11-12
CA2126244C (en) 2000-09-26
ATE150296T1 (de) 1997-04-15

Similar Documents

Publication Publication Date Title
ES2159678T3 (es) Formulaciones de aerosol en suspension.
DK0553298T3 (da) Aerosolformulering omfattende beclomethason-17,21-dipropionat
ATE203902T1 (de) Fluorchlorkohlenwasserstofffreie aerosolformulierungen
EP1277467A3 (en) Non-chlorofluorocarbon aerosol formulations
NO980858D0 (no) Farmasöytiske preparater og anordninger for administrering derav

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 717987

Country of ref document: ES